Status:
NOT_YET_RECRUITING
CMV-associated Immunomodulation in Renal Transplant Patients
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
URC-CIC Paris Descartes Necker Cochin
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Cytomegalovirus (CMV) infection has been associated with an increased risk of bacterial, fungal and viral infections in solid organ transplant recipients. The purpose of this study to evaluate if the ...
Detailed Description
Cytomegalovirus (CMV) infection remains one of the most frequent and problematic complications of solid organ transplantation. Several epidemiological studies have shown an association between CMV inf...
Eligibility Criteria
Inclusion
- st cohort :
- Age \> 18 years
- patients with end-stage renal failure programmed for kidney transplantation with a live donor
- nd cohort :
- Age \> 18 years
- kidney transplant recipient with CMV viremia
Exclusion
- \- Patients under guardianship, curatorship, legal protection.
- For patients with end-stage renal failure scheduled to receive a kidney transplant from a living donor :
- Patients with an active viral (other than CMV), bacterial or fungal infection at the time of inclusion
- patients receiving a desensitization protocol (ABO or anti-HLA)
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2029
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06976008
Start Date
October 1 2025
End Date
October 1 2029
Last Update
September 12 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Bicêtre
Le Kremlin-Bicêtre, France, 94270
2
Hôpital européen Georges Pompidou
Paris, France, 75015
3
Hôpital Necker-Enfants Malades
Paris, France, 75015
4
Insitut Pasteur
Paris, France, 75015